Contineum Therapeutics, Inc. (CTNM) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
3565 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2025 | 12/31/2024 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash, cash equivalents, and short-term investments, including: | 204,800,000 | |||
| Cash and cash equivalent | 21,943,000 | |||
| Short-term investments | 182,817,000 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 40,000 | |||
| Other undisclosed current assets | 1,588,000 | |||
| Total current assets: | 206,388,000 | |||
| Noncurrent Assets | ||||
| Operating lease, right-of-use asset | 5,467,000 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 989,000 | |||
| Other noncurrent assets | 3,000 | |||
| Total noncurrent assets: | 6,459,000 | |||
| TOTAL ASSETS: | 212,847,000 | |||
| LIABILITIES AND EQUITY | ||||
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 8,522,000 | |||
| Accounts payable | 1,811,000 | |||
| Accrued liabilities | 6,711,000 | |||
| Other undisclosed current liabilities | 1,452,000 | |||
| Total current liabilities: | 9,974,000 | |||
| Noncurrent Liabilities | ||||
| Liabilities, other than long-term debt | 4,807,000 | |||
| Operating lease, liability | 4,807,000 | |||
| Total noncurrent liabilities: | 4,807,000 | |||
| Total liabilities: | 14,781,000 | |||
| Equity | ||||
| Equity, attributable to parent, including: | 198,066,000 | |||
| Additional paid in capital | 315,371,000 | |||
| Accumulated other comprehensive income | 71,000 | |||
| Accumulated deficit | (117,402,000) | |||
| Other undisclosed equity, attributable to parent | 26,000 | |||
| Total equity: | 198,066,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 212,847,000 | |||
Income Statement (P&L) (USD)
| 12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
| Operating expenses | (50,894,000) | ||
| Operating loss: | (50,894,000) | ||
| Nonoperating income | 8,636,000 | ||
| Investment income, nonoperating | 8,905,000 | ||
| Loss from continuing operations before equity method investments, income taxes: | (42,258,000) | ||
| Other undisclosed loss from continuing operations before income taxes | |||
| Net loss: | (42,258,000) | ||
| Other undisclosed net income attributable to parent | |||
| Net loss available to common stockholders, diluted: | (42,258,000) | ||
Comprehensive Income (USD)
| 12/31/2025 | 12/31/2024 | ||
|---|---|---|---|
| Net loss: | (42,258,000) | ||
| Comprehensive loss: | (42,258,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (37,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (42,295,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.